Raloxifene Rebound Regression

References

• Beatson G. T. On treatment of inoperable cases of carcinoma of the mamma: suggestions for new method of treatment. Lancet 1896; 2, pp. 104–107, 162–165
   Google Scholar
• Haddow A., Watkinson J. M., Patterson E. Influence of synthetic oestrogens upon advanced malignant disease. BMJ 1944; 2: 393–398
   PubMedGoogle Scholar
• Escher G. C. Clinical Improvement of Inoperable Breast Carcinoma Under Steroid Treatment. Proceedings of the 1st Conference on Steroid Hormones and Mammary Carcinoma, Chicago, The Therapeutics Trials Committee of the Council on Pharmacy and Chemistry of the American Medical Association. 1944; 92–99
   Google Scholar
• Huseby R. A. Estrogen therapy in the management of advanced breast cancer. Am. J. Surg. 1954; 20: 112–124
   Google Scholar
• Howell A., Dodwell D. J., Anderson H., Redford J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol. 1992; 3: 611–617, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Jordan V. C. A therapeutic withdrawal can make a strategic advance. Ann. Oncol. 1992; 3: 587–588, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Legault-Poisson S., Jolivet J., Poisson R., Beretta-Piccoli M., Band P. R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep. 1979; 63: 1839–1841
   PubMedGoogle Scholar
• Belani C. P., Pearl P., Whitley N. O., Aisner J. Tamoxifen withdrawal response. Report of a case. Arch. Intern. Med. 1989; 149: 449–450, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Stein W., III, Hortobagyi G. N., Blumenschein G. R. Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J. Surg. Oncol. 1983; 22: 45–46, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Canney P. A., Griffiths T., Latief T. N., Priestman T. J. Clinical significance of tamoxifen withdrawal response. Lancet 1987; 1: 36, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kaufman R. J., Escher G. C. Rebound regression in advanced mammary carcinoma. Surg. Gynecol. Obstet. 1961; 113: 635–640, [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Nesto R. W., Cady B., Oberfeld R. A., Pazianos A. G., Salzman F. A. Rebound response after estrogen therapy for metastatic breast cancer. Cancer 1976; 38: 1834–1837, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dhodapkar M. V., Ingle J. N., Ahmann D. L. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 1995; 75: 43–46, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Powles T. J., Hickish T. Breast cancer response to hormone replacement therapy withdrawal. Lancet 1995; 345: 1442, (Letter.)[PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Booser D. Estrogen withdrawal as initial treatment for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 1998; 17, abstr 497
   Google Scholar
• Baker L. H., Vaitkevicius V. K. Reevaluation of rebound regression in disseminated carcinoma of the breast. Cancer 1972; 29: 1268–1271, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Osborne C. K., Coronado E. B., Robinson J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur. Cancer Clin. Oncol. 1987; 23: 1189–1196, [CROSSREF]
   Web of Science ®Google Scholar
• Gottardis M. M., Jordan V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen therapy. Cancer Res. 1988; 48: 5183–5187, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ellis M. J., Hayes D. F., Lippman M. E. Treatment of metastatic breast cancer. Diseases of the Breast2nd Ed., J. R. Harris, M. E. Lippman, M. Morrow, C. K. Osborne. Lippincott Williams & Wilkins, Philadelphia, PA 2000
   Google Scholar
• Lee A. V., Cui X., Oesterreich S. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer. Clin. Cancer Res. 2001; 7(12 Suppl.)4429s–4435s, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Song R. X., Mor G., Naftolin F., McPherson R. A., Song J., Zhang Z., Yue W., Wang J., Santen R. J. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J. Natl. Cancer Inst. Nov 21, 2001; 93(22)1673–1675, [CROSSREF]
   PubMedGoogle Scholar
• Yao K., Lee E.-S., Bentram D. J., England G., Schafer J. I., O'Regan R. M., Jordan V. C. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res. 2000; 6: 2028–2036, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cauley J. A., Norton L., Lippman M. E., Eckert S., Krueger K. A., Purdie D. W., Farrerons J., Karasik A., Mellstrom D., Ng K. W., Stepan J. J., Powles T. J., Morrow M., Costa A., Silfen S. L., Walls E. L., Schmitt H., Muchmore D. B., Jordan V. C., Ste-Marie L. G. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 2001; 65: 125–134, 2001. Erratum in: Breast Cancer Res Treat 2001; 67: 191[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vogel V. G. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Clin. Cancer Res. 2001; 7(12 Suppl.)4413s–4418s, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• DeVita V. T., Jr., Hellman S., Rosenberg S. A. Cancer: Principles and Practice of Oncology6th Ed. Lippincott Williams & Wilkins, Philadelphia, PA 2000
   Google Scholar
• Roses D. F. Breast Cancer. Churchill Livingstone, New York, NY 1999
   Google Scholar
• Hunt K. K., Robb G. L., Strom E. A., Ueno N. T. Breast Cancer (M. D. Anderson Cancer Care Series). Springer-Verlag, New York, NY 2001
   Google Scholar
• Abeloff M. D., Armitage J. O., Lichter A. S., Niederhuber J. E. Clinical Oncology2nd Ed. Churchill Livingstone, Philadelphia, PA 2000
   Google Scholar
• Kaufmann M. A review of endocrine options for the treatment of advanced breast cancer. Oncology 1997; 54(Suppl. 2)2–5, Review[PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Ross M. B., Buzdar A. U., Blumenschein G. R. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer Feb, 1982; 49(1)413–417, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Castiglione-Gertsch M., Pampallona S., Varini M., Cavalli F., Brunner K., Senn H. J., Goldhirsch A., Metzger U. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?. Ann. Oncol. Nov, 1993; 4: 735–740
   PubMed Web of Science ®Google Scholar
• Gill P. G., Gebski V., Snyder R., Burns I., Levi J., Byrne M., Coates A. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann. Oncol. Nov, 1993; 4: 741–744, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Davidson N. E., Levine M. Breast cancer consensus meetings: vive la difference?. J. Clin. Oncol. 2002; 20: 1719–1720, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Henderson C. I. A rose is no longer a rose. J. Clin. Oncol. 2002; 20: 3365–3368, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar